AU729643B2 - Polypeptide conjugates for transporting substances across cell membranes - Google Patents

Polypeptide conjugates for transporting substances across cell membranes Download PDF

Info

Publication number
AU729643B2
AU729643B2 AU29298/97A AU2929897A AU729643B2 AU 729643 B2 AU729643 B2 AU 729643B2 AU 29298/97 A AU29298/97 A AU 29298/97A AU 2929897 A AU2929897 A AU 2929897A AU 729643 B2 AU729643 B2 AU 729643B2
Authority
AU
Australia
Prior art keywords
polypeptide
acid
compound
composition
terminus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU29298/97A
Other languages
English (en)
Other versions
AU2929897A (en
Inventor
James E Summerton
Dwight D Weller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sarepta Therapeutics Inc
Original Assignee
Antivirals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antivirals Inc filed Critical Antivirals Inc
Publication of AU2929897A publication Critical patent/AU2929897A/en
Application granted granted Critical
Publication of AU729643B2 publication Critical patent/AU729643B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU29298/97A 1996-05-01 1997-04-30 Polypeptide conjugates for transporting substances across cell membranes Ceased AU729643B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1634796P 1996-05-01 1996-05-01
US60/016347 1996-05-01
US2860996P 1996-10-23 1996-10-23
US60/028609 1996-10-23
PCT/US1997/007335 WO1997040854A2 (en) 1996-05-01 1997-04-30 Polypeptide conjugates for transporting substances across cell membranes

Publications (2)

Publication Number Publication Date
AU2929897A AU2929897A (en) 1997-11-19
AU729643B2 true AU729643B2 (en) 2001-02-08

Family

ID=26688485

Family Applications (1)

Application Number Title Priority Date Filing Date
AU29298/97A Ceased AU729643B2 (en) 1996-05-01 1997-04-30 Polypeptide conjugates for transporting substances across cell membranes

Country Status (5)

Country Link
EP (1) EP0966303A2 (enrdf_load_stackoverflow)
JP (1) JP2000509394A (enrdf_load_stackoverflow)
AU (1) AU729643B2 (enrdf_load_stackoverflow)
CA (1) CA2252706A1 (enrdf_load_stackoverflow)
WO (1) WO1997040854A2 (enrdf_load_stackoverflow)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998032467A2 (en) * 1997-01-24 1998-07-30 Antivirals, Inc. Method and conjugate for treating h. pylori infection
AU6278298A (en) * 1997-02-14 1998-09-08 Salk Institute For Biological Studies, The Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
EP0975370B9 (en) 1997-05-21 2004-11-03 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
US6958148B1 (en) 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
US20020064520A1 (en) * 1999-08-19 2002-05-30 Yanina Rozenberg Targeted artificial gene delivery
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
JP2003507438A (ja) 1999-08-24 2003-02-25 セルゲイト， インコーポレイテッド オリゴアルギニン部分を使用する上皮組織を横切るおよび上皮組織内への薬物送達の増強
AU2001271873A1 (en) 2000-07-06 2002-01-21 Avi Biopharma, Inc. Transforming growth factor beta (TGF-beta) blocking agent-treated stem cell composition and method
DK2364734T3 (en) 2000-07-21 2017-10-30 Revance Therapeutics Inc Biological multicomponent transport systems
JP2004523480A (ja) * 2000-08-22 2004-08-05 ニュー リバー ファーマシューティカルズ， インコーポレイテッド 活性作用物質送達系ならびに活性作用物質の保護および投与方法
JP2006516948A (ja) * 2000-11-14 2006-07-13 ニュー リバー ファーマシューティカルズ インコーポレイテッド 硫酸アバカビルを含有する新規な薬剤化合物および同化合物の製造ならびに使用方法
EP2316468A1 (en) * 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
BRPI0406647A (pt) 2003-01-06 2005-12-06 Angiochem Inc Método para transportar um composto através da barreira sanguìnea do cérebro
CA2553104A1 (en) 2004-01-23 2005-08-11 Avi Biopharma, Inc. Antisense oligomers and methods for inducing immune tolerance and immunosuppression
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
WO2005120546A2 (en) 2004-03-03 2005-12-22 Essentia Biosystems, Inc. Compositions and methods for topical diagnostic and therapeutic transport
PT1766012E (pt) 2004-07-02 2011-09-05 Avi Biopharma Inc Método e composto antisense antibacteriano
ES2852549T3 (es) 2005-02-09 2021-09-13 Sarepta Therapeutics Inc Composición antisentido para tratamiento de la atrofia muscular
PT1859041E (pt) 2005-02-18 2012-06-19 Angiochem Inc Moléculas para transportar um composto através da barreira hematoencefálica
NZ560799A (en) 2005-03-03 2009-10-30 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of an oligopeptide
JP2008531732A (ja) 2005-03-03 2008-08-14 ルバンス セラピュティックス インク． ボツリヌス毒素の局所塗布及び経皮送達のための組成物及び方法
EP1915161B1 (en) 2005-07-13 2017-04-26 Sarepta Therapeutics, Inc. Antisense antibacterial method and compound
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
CN101262890B (zh) 2005-07-15 2015-08-26 安吉奥化学公司 抑肽酶多肽作为载体在药物缀合物中的用途
US8501704B2 (en) 2005-11-08 2013-08-06 Sarepta Therapeutics, Inc. Immunosuppression compound and treatment method
EP1935434A1 (en) * 2006-12-19 2008-06-25 Novosom AG Construction and use of transfection enhancer elements
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
CA2718961C (en) 2008-03-20 2014-12-16 University Of Florida Research Foundation, Inc. Enhancing vessel lesion homing and repair potential of stem cells
EP2143726A1 (en) * 2008-07-11 2010-01-13 Novosom AG Nucleic acid comprising zwitterionic nucleotides
AU2009304560A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of GLP-1 agonists and uses thereof
JP5759379B2 (ja) 2008-12-05 2015-08-05 アンジオケム インコーポレーテッド ニューロテンシンまたはニューロテンシンアナログおよびその使用
US8592386B2 (en) * 2008-12-17 2013-11-26 Sarepta Therapeutics, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
US9173891B2 (en) 2009-04-20 2015-11-03 Angiochem, Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
CN102803500B (zh) 2009-06-05 2014-11-19 13治疗有限公司 免疫调节肽和使用方法
EP2448965A4 (en) 2009-07-02 2015-02-11 Angiochem Inc MULTIMEPEPTID CONJUGATES AND ITS USES
TWI620756B (zh) 2010-05-28 2018-04-11 薩羅塔治療公司 具有經修飾之單元間連結及／或末端基團之寡核苷酸類似物
US10017763B2 (en) 2010-09-03 2018-07-10 Sarepta Therapeutics, Inc. dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups
US8580748B2 (en) 2011-04-06 2013-11-12 13Therapeutics, Inc. Peptides for the treatment of hearing
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
EP2780299A4 (en) 2011-11-18 2015-04-22 Sarepta Therapeutics Inc FUNCTION MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF
CA2868174A1 (en) 2012-03-20 2013-09-26 Sarepta Therapeutics, Inc. Boronic acid conjugates of oligonucleotide analogues
GB201210358D0 (en) * 2012-06-12 2012-07-25 Polytherics Ltd Complexes
CA2881602A1 (en) 2012-08-14 2014-02-20 Angiochem Inc. Peptide-dendrimer conjugates and uses thereof
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
EP3302489A4 (en) 2015-06-04 2019-02-06 Sarepta Therapeutics, Inc. METHOD AND COMPOUNDS FOR THE TREATMENT OF DISEASES AND SUFFERING IN CONNECTION WITH LYMPHOCYTES
ES2826827T3 (es) 2015-06-15 2021-05-19 Angiochem Inc Métodos para el tratamiento de carcinomatosis leptomeníngea
KR20180105115A (ko) * 2015-10-07 2018-09-27 코르메딕스, 인코포레이티드 타우로리딘의 피부-침투성 제제

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1541436A (en) * 1976-02-02 1979-02-28 Searle & Co Immunological materials
WO1992010212A1 (en) * 1990-12-05 1992-06-25 Farmitalia Carlo Erba Srl Anthracycline-conjugates

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9017024D0 (en) * 1990-08-03 1990-09-19 Erba Carlo Spa New linker for bioactive agents
CZ297979B6 (cs) * 1996-03-12 2007-05-16 Pg-Txl Company, L. P. Kompozice obsahující protinádorové lécivo konjugované s ve vode rozpustným polymerem, její pouzití pro výrobu léciva a implantovatelná lékarská pomucka

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1541436A (en) * 1976-02-02 1979-02-28 Searle & Co Immunological materials
WO1992010212A1 (en) * 1990-12-05 1992-06-25 Farmitalia Carlo Erba Srl Anthracycline-conjugates

Also Published As

Publication number Publication date
EP0966303A2 (en) 1999-12-29
CA2252706A1 (en) 1997-11-06
WO1997040854A2 (en) 1997-11-06
JP2000509394A (ja) 2000-07-25
WO1997040854A3 (en) 1998-03-12
AU2929897A (en) 1997-11-19

Similar Documents

Publication Publication Date Title
AU729643B2 (en) Polypeptide conjugates for transporting substances across cell membranes
US6030941A (en) Polymer composition for delivering substances in living organisms
Dal Corso et al. Innovative linker strategies for tumor‐targeted drug conjugates
AU2002306500B2 (en) Transporters comprising spaced arginine moieties
US6379660B1 (en) Nitric oxide-releasing 1-[(2-carboxylato)pyrrolidin-1-yl] diazen-1-ium-1,2-diolates and composition comprising same
Christie et al. Design strategies to improve soluble macromolecular delivery constructs
JP3731899B2 (ja) 酸化窒素放出生体高分子含有医薬組成物
AU699387B2 (en) Use of nitric oxide-releasing agents for reducing metastasis risk
US7169814B2 (en) Guanidinium transport reagents and conjugates
US6593292B1 (en) Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6730293B1 (en) Compositions and methods for treating inflammatory diseases of the skin
EP0700295A1 (en) Vitamin b 12? mediated oral delivery systems for gcsf and epo
JP2004530657A (ja) 上皮組織にわたるおよび上皮組織への薬物送達を増強するための組成物および方法
JP2003523982A (ja) 生体膜および生体組織を横切る薬物送達を増強するための、組成物および方法
WO2000074721A1 (en) Vitamin directed dual targeting therapy
Shi et al. Intelligent “Peptide-Gathering Mechanical Arm” tames wild “Trojan-Horse” peptides for the controlled delivery of cancer nanotherapeutics
EP1695717A1 (en) Transport of nano-and macromolecular structures into cytoplasm and nucleus of cells
US20030068379A1 (en) Multifunctional carrier for the delivery of a pharmacological agent or genetic material into a cell
US9943606B2 (en) Dendritic polypeptide-based nanocarriers for the delivery of therapeutic agents
US20080031883A1 (en) Condition-dependent, multiple target delivery system
US20050220754A1 (en) Vitamin directed targeting therapy
Van Heeswijk et al. Synthesis, characterization and antitumor activity of macromolecular prodrugs of adriamycin
US20100227798A1 (en) Use of the staudinger ligation in in vivo assembly of a biologically active compound
US12285437B2 (en) Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity
US8772248B2 (en) Drug delivery system

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)